The $100 Billion "Fat" Pill: Can Ozempic Make India Rich? (Summary) | Fittrjc wisdom | Think School скачать в хорошем качестве

The $100 Billion "Fat" Pill: Can Ozempic Make India Rich? (Summary) | Fittrjc wisdom | Think School

Is India about to become the world's weight-loss factory? 🇮🇳💉 In this video, we summarize the explosive Think School case study featuring Fittr founder Jitendra Chouksey (@fittrjc) on the "Ozempic Revolution." With the global patent for Semaglutide (Ozempic/Wegovy) set to expire in India in March 2026, Indian pharmaceutical giants are gearing up for a "Gold Rush." The opportunity is massive: becoming the global supplier for the most demanded drug on earth. But at what cost? We break down the 3 critical angles: The Business Case: Why companies like Sun Pharma & Cipla are racing to make generic versions. The "Diabesity" Crisis: Why India isn't just the producer, but the biggest victim of the problem. Fittrjc's Warning: The biological price of "easy weight loss"—muscle wasting, "Ozempic Face," and why you can't inject discipline. Is this the next IT boom for India, or a health disaster waiting to happen? 👇 Discussion: Would you take a "Magic Injection" to lose weight if it was cheap and made in India? Or do you agree with JC that there are no shortcuts? Let me know below! #OzempicIndia #ThinkSchool #Fittrjc #IndianPharma #WeightLossJourney #Semaglutide #BusinessCaseStudy #IndianEconomy #HealthTech #SunPharma #JitendraChouksey